These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12411975)

  • 41. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-molecular weight heparins.
    Talley JD
    J Ark Med Soc; 1997 Apr; 93(11):555-6. PubMed ID: 9114648
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical potential of antithrombotic drugs in coronary syndromes.
    Turpie AG
    Am J Cardiol; 1998 Sep; 82(5B):11L-14L. PubMed ID: 9737474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins].
    López-Sendón J; López de Sá E; Rubio Sanz R; Delcán Domínguez JL
    Rev Esp Cardiol; 1999; 52 Suppl 1():76-89. PubMed ID: 10364817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-molecular-weight heparin in patients with non-ST-segment elevation acute coronary syndrome: role in the emergency department.
    Goodman SG
    J Emerg Med; 2000 Oct; 19(3 Suppl):3S-11S. PubMed ID: 11050378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
    Borja J; Olivella P
    Med Clin (Barc); 2000 Nov; 115(15):583-6. PubMed ID: 11141394
    [No Abstract]   [Full Text] [Related]  

  • 49. New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials.
    Cohen M
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S343-52. PubMed ID: 9628448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions?
    Fry ET
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I8-11. PubMed ID: 11286313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Krulewitz A
    N Engl J Med; 1998 Jan; 338(2):130; author reply 131. PubMed ID: 9424584
    [No Abstract]   [Full Text] [Related]  

  • 53. Low-molecular-weight heparins and unstable angina--current perspectives.
    Turpie AG
    Haemostasis; 1997; 27 Suppl 1():19-24. PubMed ID: 9439754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease.
    Goodall AH; Knight C
    N Engl J Med; 1998 Jan; 338(2):130-1. PubMed ID: 9424585
    [No Abstract]   [Full Text] [Related]  

  • 55. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations.
    Pineo GF; Hull RD
    Med Clin North Am; 1998 May; 82(3):587-99. PubMed ID: 9646781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low--molecular weight heparins and unfractionated heparins during primary coronary intervention.
    Cavallino C; Santagostino M; Facchini E; Di Ruocco V; Rognoni A
    Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):96-100. PubMed ID: 22963494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-molecular weight heparins in coronary artery disease.
    Hunt D
    Curr Atheroscler Rep; 2001 Mar; 3(2):163-8. PubMed ID: 11177661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
    Husted S; Becker R; Kher A
    Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.